| DGX |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.82 vs. cons $2.75 |
MEDIUM |
| DGX |
Report |
Net revenues |
BEAT |
pred ~$3.01B vs. cons $2.97B |
MEDIUM |
| DGX |
Report |
Organic revenue growth |
BEAT |
pred ~8.4% vs. cons 7.2% |
MEDIUM |
| DGX |
Guide |
FY2026 net-revenue guidance |
BETTER |
guide ~$11.94B vs. cons $11.87B (FY2026) |
MEDIUM |
| DGX |
Guide |
FY2026 adjusted diluted-EPS guidance |
BETTER |
guide ~$10.92 vs. cons $10.78 (FY2026) |
MEDIUM |
| DGX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| DGX |
Return |
5-day cumulative residual |
+4.2% (FOLLOW-THROUGH) |
A ~$0.14 FY2026 adjusted-EPS guide midpoint versus ~$10.78 consensus supports upward out-period estimate revisions: the ~$0.07 quarterly EPS beat and ~$0.04B revenue beat are reinforced by a ~$0.14 full-year EPS guide increase rather than offset by an implicit second-half cut. |
MEDIUM |